Correlates of Blood Pressure and Cholesterol Level Testing Among a Socially-Disadvantaged Population in Poland

Małgorzata Znyk 1,*, Kinga Polańska 1, Leokadia Bąk-Romaniszyn 2 and Dorota Kaleta 1

1 Department of Hygiene and Epidemiology, Medical University of Lodz, 90-647 Lodz, Poland; kinga.polanska@umed.lodz.pl (K.P.); dkaleta@op.pl (D.K.)
2 Department of Nutrition in Digestive Tract Diseases, Medical University of Lodz, 93-338 Lodz, Poland; leokadia.bak-romaniszyn@umed.lodz.pl
* Correspondence: znyk@poczta.onet.pl; Tel.: +48-426-781-688

Received: 18 February 2020; Accepted: 13 March 2020; Published: 23 March 2020

Abstract: As part of cardiovascular disease prevention, the performance of BMI determination, blood pressure measurement, biochemical tests, as well as a lifestyle-related risk assessment are recommended. The aim of this study was to evaluate the correlates of blood pressure and cholesterol level testing among a socially-disadvantaged population in Poland. This cross-sectional study was performed between 2015 and 2016 among 1710 beneficiaries of government welfare assistance. Face-to-face interviews conducted by trained staff at each participant’s place of residence allowed for completion of questionnaires that covered socio-demographic, health and lifestyle-related information. Sixty-five percent of the participants declared a blood pressure and 27% of them cholesterol level testing at least once within the year proceeding the study. A higher chance of having blood pressure testing was observed among the women (OR = 1.5; p = 0.002) and people with high blood pressure (OR = 3.9; p < 0.001). The women (OR = 1.4; p = 0.04) and older people (OR = 1.9; p = 0.02; OR = 2.6; p < 0.001, OR = 2.7; p = 0.002, for the following age groups: 30-39, 40-49, 50-59 years respectively), the respondents who declared health problems such as heart attack (OR = 3.0; p = 0.04), high blood pressure (OR = 2.3; p < 0.001) and type 2 diabetes (OR = 3.3; p = 0.004) and those with a family history of chronic diseases (OR = 1.5; p = 0.03) had a higher chance of cholesterol level checking. Higher healthy lifestyle index, indicating that the study participants have followed almost all of the studied lifestyle-related recommendations, was a significant correlate of cholesterol level testing (OR = 1.7; p = 0.006). Actions that promote lifestyle changes, blood pressure, and cholesterol level testing should take into account the needs of the disadvantaged population and should especially target men, people with existing chronic diseases, and those with unfavorable lifestyle characteristics. With respect to the socially-disadvantaged population, the social assistance institutions and outpatient clinics are the best places to conduct activities promoting a healthy lifestyle. The most commonly applied strategies to promote lifestyle changes can cover risk assessment, increasing awareness, emotional support and encouragement, as well as a referral to specialists.

Keywords: blood pressure testing; cholesterol level testing; lifestyle factors; healthy lifestyle index; correlates

1. Introduction

Chronic diseases constitute a serious health problem in the world. According to the World Health Organization (WHO), around 41 million deaths that occurred in 2016 were due to non-communicable diseases (NCD), accounting for 71% of the total 57 million deaths [1,2]. Cardiovascular diseases (CVD) are one of the main causes of morbidity and mortality, which account for 44% of all deaths from
NCDs [1,3]. CVDs kill over 4 million people in Europe each year. Generally, the number of deaths due to CVDs is higher among women (2.2 million) than among men (1.8 million), although deaths due to cardiovascular causes in people younger than 65 years of age are more common among men than women (490,000 vs. 193,000) [4].

Arterial hypertension (AH) is the key dominant risk factor for CVDs [5]. The diseases attributed to hypertension include: stroke, heart failure, ischemic heart disease, hypertensive retinopathy, renal failure [5]. AH is also associated with diabetic, endocrine, nephrological diseases and osteoporosis [6]. The American Heart Association/American College of Cardiology (AHA/ACC) guidelines treat all blood pressure (BP) values above 130/80 mmHg as hypertension [7]. Two stages of hypertension have been defined: stage 1 of hypertension in the range of 130–139/80–89 mmHg, and stage 2 for any pressure equal or above 140/90 mmHg. According to the guidelines of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) from 2018 and the Polish Society of Hypertension (PTNT) from 2015, normal BP values in an adult were defined as less than 140/90 mmHg [8]. It is recommended to divide BP into optimal (below 120/80 mmHg), normal (120–129/80–84 mmHg), high normal (130–139/85–89 mmHg) and grades of hypertension 1–3 [8]. Values in the 140–159/90–99 mmHg ranges are defined as first stage hypertension, in the 160–179/100–109 mmHg ranges as second stage hypertension, and above 180/110 mmHg, third stage [9]. More precisely, following ESC guidelines, people under 65 years of age should have systolic blood pressure (SBP) of 120–129 mmHg, regardless of whether they have only arterial pressure or are associated with co-morbidities. Target SBP values within 130–139 mmHg are recommended for older patients over 65–80 years of age. Target SBP values in the range 130–139 mmHg are recommended for patients over 80 years of age subject to good tolerability. Target diastolic blood pressure (DBP) values below 80 mmHg should be considered in all hypertensive subjects, regardless of the risk level and co-morbidities [8]. It is estimated that AH equal to or exceeding 140/90 mmHg occurs in more than 25% of the world’s population. About 10 million people in Poland (32% of the adult population) suffer from that condition [10]. In order to assess a cardiovascular risk of patients with hypertension the following have been taken into account: uric acid levels, accelerated heart rate as well as socioeconomic and psycho-sociological factors [8].

An important factor, contributing to about one third of deaths caused by all CVDs, is elevated blood cholesterol [11]. Cholesterol may contribute to the development of pathological conditions resulting from both: accumulation of its particles in the body as well as disorders in their metabolism. Its participation in pathogenesis has been described, among others in the case of neurodegenerative diseases, CVDs, kidney diseases and cancer [12]. The basic tests recommended in the diagnosis of lipid disorders include: total cholesterol (TC), triglycerides (TG), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), and non-HDL cholesterol (non-HDL-C). LDL-C is the main lipid parameter used in the diagnosis of lipid disorders, risk assessment and treatment [3,13]. The recommended level of TC in the blood is below 200 mg/dL (5.2 mmol/L). Elevated cholesterol is defined as 200–250 mg/dL (5.1–6.5 mmol/L). We talk about a significantly elevated level when its value exceeds 250 mg/dL (> 6.5 mmol/L). The ESH/ESC guidelines state that cholesterol intake should be reduced to <300 mg/day, especially in people with high plasma levels [3]. The Polish Diabetes Association also reports that, in patients with elevated LDL cholesterol (≥ 100 mg/dl), dietary cholesterol should be reduced to <200 mg/day [14].

Due to ageing of the population, a non-healthy lifestyle and the increase in average body weight, the frequency of diagnosis of AH in the world will increase. Forecasts indicate that by 2025 the number of people with hypertension will have increased by 15–20%, reaching about 1.5 billion [15].

A lifestyle modification is the most effective method for preventing development of AH, while in the early diagnosis of the disease screening BP measurements performed at least once a year is of key importance [16].

BP measurement at a physician’s office or outpatient clinic remains the gold standard for diagnosing AH. Current ESH/ESC guidelines for the management of hypertension point to the high value of
extra-office BP measurements—home blood pressure monitoring (HBPM) and 24-h ambulatory blood pressure monitoring (ABPM) in establishing the diagnosis and indications for AH treatment [17].

As part of the Cardiovascular Disease Prevention Program introduced to primary healthcare, biochemical tests (concentration of cholesterol, triglycerides, and glucose), BP measurement, Body Mass Index (BMI) determination, and risk assessment according to the Systematic COronary Risk Evaluation system (SCORE), are recommended. Persons covered by the program undergo educational activities in the field of a healthy lifestyle and patients diagnosed with CVDs are referred for a further diagnosis and specialist treatment [18].

Physicians should not only focus on the clinical treatment of an existing disease, but also recognize the health needs of their patients through an active discussion, identifying positive health behaviors, monitoring health state of their patients and providing support offering lifestyle advice [19–22]. A properly educated patient will participate in the process of prevention and treatment more effectively. Primary care physicians know their patients and can play a key role in counseling a healthy lifestyle. In Polish regulations in the field of activities aimed at the prevention of diseases, it is a primary care physician who identifies health hazards and patients’ risk factors and also implements actions aimed at their reduction [23].

Cooperation between medical staff and a patient and compliance with a physician’s recommendations is a significant challenge in the treatment of chronic diseases. The aim of the study was to evaluate the correlates of BP and cholesterol level testing among a socially-disadvantaged population in Poland. This could be crucial for implementation of targeted preventive measures among this vulnerable population.

2. Material and Methods

2.1. Study Design and Population

Characteristics of the examined region, methodology, and the study sample have been published elsewhere [24–26]. Briefly, this cross-sectional study that covered beneficiaries of government welfare assistance was performed between October 2015 and February 2016 among residents of Piotrkowski district aged 18–59 years. For the selection of the study sample, the poverty threshold as adopted by the social assistance institutions was applied (income of no more than 634 PLN (148 Euro) for a single person monthly, and 514 PLN (120 Euro) for a family member monthly). Taking into account age and income limit, 3636 individuals met the inclusion criteria and 1817 agreed to participate in the study (50.0%). Of this group, 1710 people (94.1%) had core data available for the current analyses.

The Bioethics Committee of the Medical University in Lodz granted approval for this study (RNN/243/15/KE) and informed consents were obtained from all the study participants.

2.2. Study Variables

Face-to-face interviews conducted by trained staff at each participant’s place of residence allowed for completion of the questionnaires. The questionnaire covered socio-demographic, health status and lifestyle-related information. In the analyses under this study, a respondent’s sex (male, female) and age (categorized as: <30, 30–39, 40–49, 50–59 years) were selected. The second group of questions focused on a health status including: subjective health state (categorized as: fair/rather fair, neither fair nor poor, rather poor/poor) and a number of specified health problems noted within the past month (categorized as: none, 1–3, 4–6, >7). The respondents were also asked if they have had heart attack, high blood pressure (HBP), or type 2 diabetes (yes, no). The family history of chronic diseases, including: heart attack, coronary artery disease, stroke, cancer, HBP, diabetes, high cholesterol level, and overweight/obesity was also reported (categorized as: yes–if any and no–if neither was indicated). Two dependent variables were considered in the current analyses: (1) BP and (2) cholesterol level testing. An answer stating that the respondents had BP or cholesterol level testing done within the
year proceeding the study was considered as positive and the other options (never, between one and five years, more than five years ago, I don’t know) as negative.

The participants were also asked several questions that allowed us to describe five lifestyle-related characteristics: (1) smoking status, (2) diet, (3) height and weight, (4) alcohol consumption, and (5) recreational physical activity. The pattern of each lifestyle-related characteristics was defined as a single healthy lifestyle indicator (HLI) coded as 1 if a respondent followed healthy lifestyle recommendations and as 0 if the recommendations were not followed. Finally, the healthy lifestyle index (range, 0–5) was created by adding up all the five HLIs.

The study participants were asked about their smoking status. Those who answered that they had never smoked cigarettes received 1 for HLI. For the current smoking status (including daily or occasional smoking) the following coding was given: yes: HLI = 0; no: HLI = 1 [24]. Details regarding each participant’s diet and its categorization according to the existing guidelines were published previously [25]. For the purpose of the current analysis HLI equal 1 was given to the participants with healthy or average dietary habits and HLI equal 0 to those who had not followed the recommendations. Healthy weight was defined as BMI (based on a participant’s height (m) and weight (kg)) between 18.5 and 24.9 (kg/m²) (HLI = 1) [27]. For alcohol consumption, information regarding frequency, intensity (units of alcohol per day and binge drinking), and type of alcohol (wine, beer, spirit) was collected. According to the existing guidelines, frequent and high-quantity alcohol consumption is related to a poorer health-related quality of life. It is also recommended that women should consume up to one and men up to two units of alcohol per day [28]. HLI equal to 1 was dedicated to the participants who followed the recommendations. Finally, the participants were asked several questions about their leisure-time physical activity (LTPA) (including type, duration, and frequency of LTPA) and commuting physical activity (CPA) as described previously [26]. The participants who achieved criteria for the recommended level of recreational physical activity based on LTPA or CPA received, HLI = 1 [29].

2.3. Statistical Analysis

For the variables included in the study, the percentage share of individual categories of the responses in the study group was calculated.

The unadjusted and adjusted odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to identify the correlates of performing BP testing and cholesterol level testing within the year proceeding the study. The Mantel–Haenszel chi-square statistics were used. Multivariate models included all of the studied variables. The significance level of statistical inference was set at p < 0.05. STATISTICA version 10.0 (Dell Software, Arizona, CA, USA) was used to perform the statistical analysis.

3. Results

3.1. Characteristics of the Study Population

The women constituted 67% of the study population (Table 1). The mean age of the respondents was 39.2 ± 7.7 years. Most of the subjects described their health status as fair or rather fair and one in tenth as rather poor or poor. About 1% of the participants had heart attack, 2.5% type 2 diabetes and 12% were diagnosed with HBP. Family history of any chronic diseases was indicated by almost 70% of the participants. More than 37% of the beneficiaries of government welfare assistance were smokers. The health lifestyle recommendations were followed by 56% for alcohol consumption, 26% for a recreational physical activity and 9% for a diet. The recommended range of BMI (between 18.5 and 24.9 (kg/m²)) was reported by 43% of the participants. The healthy lifestyle index (summed up 5 analyzed lifestyle features) between 0 to 3 was noted for 84% of the subjects and only 10% gained 4 out of 5 points. The maximum number of points (which means that the respondents followed all 5 lifestyle-related recommendations) was achieved by 11 people only (0.6%).
### Table 1. Characteristics of the study participants.

| Variables                          | Total N = 1710 | Blood Pressure Testing N = 1114 | Cholesterol Level Testing N = 460 |
|------------------------------------|---------------|---------------------------------|-----------------------------------|
|                                    | 100%          | 65.1%                           | 26.9%                             |
| **N**                              | **%**         | **N**                           | **%**                             |
| **Sex**                            |               |                                 |                                   |
| Male                               | 568           | 33.2                            | 343                               | 60.4                            | 131                           | 23.1                           |
| Female                             | 1142          | 66.8                            | 771                               | 67.5                            | 329                           | 28.8                           |
| **Age (years)**                    |               |                                 |                                   |
| <30                                | 194           | 11.3                            | 116                               | 59.8                            | 27                            | 13.9                           |
| 30-39                              | 725           | 42.4                            | 462                               | 63.7                            | 165                           | 22.8                           |
| 40-49                              | 578           | 33.8                            | 385                               | 66.6                            | 192                           | 33.2                           |
| 50-59                              | 213           | 12.5                            | 151                               | 70.9                            | 76                            | 35.7                           |
| **Subjective health state**        |               |                                 |                                   |
| Fair/rather fair                   | 1121          | 65.5                            | 685                               | 61.1                            | 252                           | 22.5                           |
| Neither fair nor poor              | 407           | 23.8                            | 300                               | 73.7                            | 135                           | 33.2                           |
| Rather poor/poor                   | 182           | 10.6                            | 129                               | 70.9                            | 73                            | 40.1                           |
| **Number of health problems**      |               |                                 |                                   |
| 0                                  | 231           | 13.5                            | 139                               | 60.2                            | 44                            | 19.0                           |
| 1-3                                | 900           | 52.6                            | 564                               | 62.7                            | 227                           | 25.2                           |
| 4-6                                | 448           | 26.2                            | 323                               | 72.1                            | 141                           | 38.2                           |
| >7                                 | 97            | 5.7                             | 66                                | 68.0                            | 41                            | 42.3                           |
| Missing data                       | 34            | 2.0                             | 22                                | 64.7                            | 7                             | 20.6                           |
| **Heart attack**                   |               |                                 |                                   |
| Yes                                | 22            | 1.3                             | 18                                | 81.8                            | 15                            | 68.2                           |
| No                                 | 1688          | 98.7                            | 1096                              | 64.9                            | 445                           | 26.4                           |
| **High blood pressure**            |               |                                 |                                   |
| Yes                                | 197           | 11.5                            | 172                               | 87.3                            | 105                           | 53.3                           |
| No                                 | 1513          | 88.5                            | 942                               | 62.3                            | 355                           | 23.5                           |
| **Total HLIDiabetes**              |               |                                 |                                   |
| Yes                                | 42            | 2.5                             | 34                                | 81.0                            | 27                            | 64.3                           |
| No                                 | 1668          | 97.5                            | 1080                              | 64.7                            | 433                           | 26.0                           |
| **Family history of chronic diseases** |            |                                 |                                   |
| Yes                                | 1175          | 68.7                            | 803                               | 68.3                            | 346                           | 29.4                           |
| No                                 | 318           | 18.6                            | 187                               | 58.8                            | 58                            | 18.2                           |
| I don’t know or missing            | 217           | 12.7                            | 124                               | 57.1                            | 56                            | 25.8                           |
| **Smoking HLI**                    |               |                                 |                                   |
| 1                                  | 1071          | 62.6                            | 711                               | 66.4                            | 308                           | 28.8                           |
| 0                                  | 637           | 37.3                            | 402                               | 63.1                            | 152                           | 23.9                           |
| Missing data                       | 2             | 0.1                             | 1                                 | 50.0                            | 0                             | 0.0                            |
| **Diet HLI**                       |               |                                 |                                   |
| 1                                  | 160           | 9.4                             | 106                               | 66.3                            | 53                            | 33.1                           |
| 0                                  | 1550          | 90.6                            | 1008                              | 65.0                            | 407                           | 26.3                           |
| **Recreational physical activity** |               |                                 |                                   |
| HLI 1                              | 445           | 26.0                            | 301                               | 67.6                            | 126                           | 28.3                           |
| 0                                  | 1238          | 72.4                            | 798                               | 64.5                            | 326                           | 26.3                           |
| Missing data                       | 27            | 1.6                             | 15                                | 55.6                            | 8                             | 29.6                           |
| **Alcohol HLI**                    |               |                                 |                                   |
| 1                                  | 950           | 55.6                            | 634                               | 66.7                            | 286                           | 30.1                           |
| 0                                  | 694           | 40.6                            | 445                               | 64.1                            | 162                           | 23.3                           |
| Missing data                       | 66            | 3.8                             | 35                                | 53.0                            | 12                            | 18.2                           |
| **BMI HLI**                        |               |                                 |                                   |
| 1                                  | 732           | 42.8                            | 491                               | 67.1                            | 201                           | 27.5                           |
| 0                                  | 978           | 57.2                            | 623                               | 63.7                            | 259                           | 26.5                           |
| **Total HLI**                      |               |                                 |                                   |
| 0                                  | 154           | 9.0                             | 100                               | 64.9                            | 38                            | 25.7                           |
| 1                                  | 401           | 23.5                            | 253                               | 63.1                            | 97                            | 24.2                           |
| 2                                  | 546           | 31.9                            | 349                               | 63.9                            | 141                           | 25.8                           |
| 3                                  | 331           | 19.4                            | 231                               | 69.8                            | 94                            | 28.4                           |
| 4                                  | 173           | 10.1                            | 122                               | 70.5                            | 66                            | 38.2                           |
| 5                                  | 11            | 0.6                             | 9                                 | 81.8                            | 5                             | 45.5                           |
| Missing data                       | 94            | 5.5                             | 50                                | 53.2                            | 19                            | 20.2                           |

HLI—healthy lifestyle indicator. BMI—body mass index.
3.2. Correlates of Blood Pressure and Cholesterol Level Testing

Sixty-five percent of the beneficiaries of government welfare assistance declared BP testing at least once within the year proceeding the study (Table 1). Much fewer participants had their cholesterol level checked (27%).

The results of the univariate and multivariate analyses of the correlates of BP and cholesterol level testing among the socially-disadvantaged population in Poland are presented in Table 2. A higher chance of having BP testing was observed for the women (OR = 1.5; \( p = 0.002 \)) and people with a diagnosed HBP (OR = 3.9; \( p < 0.001 \)). The individuals with the family history of chronic diseases had BP checked more frequently; however, the results were of borderline significance (OR = 1.3; \( p = 0.06 \)). More and stronger correlates were noted for cholesterol level testing. The women (OR = 1.4; \( p = 0.04 \)) and older people (OR = 1.9; \( p = 0.02 \); OR = 2.6; \( p < 0.001 \); OR = 2.7; \( p = 0.002 \), for the following age groups: 30-39, 40-49, 50-59 years, respectively) had a higher chance of having cholesterol level testing as compared to the men and people younger than 30 years of age. The respondents who declared health problems such as heart attack (OR = 3.0; \( p = 0.04 \)), HBP (OR = 2.3; \( p < 0.001 \)), type 2 diabetes (OR = 3.3; \( p = 0.004 \)), and those with family history of chronic diseases (OR = 1.5; \( p = 0.03 \)) also had a higher chance of cholesterol level checking. A higher healthy lifestyle index, indicating that the study participants have followed almost all of the studied recommendations related to the lifestyle, was a significant correlate of cholesterol level testing (OR = 1.7; \( p = 0.006 \)).

Table 2. Chance of performing blood pressure and cholesterol level testing.

| Variable                  | Chance of Performing Blood Pressure Testing | Chance of Performing Cholesterol Level Testing |
|---------------------------|--------------------------------------------|-----------------------------------------------|
|                           | Unadjusted Model | Adjusted Model | Unadjusted Model | Adjusted Model |
|                           | OR (95% CI)      | \( p \)-Value | OR (95% CI)      | \( p \)-Value |
| Sex                       | Sex             |                | Sex             |                |
| Male                      | 1.00 Ref.       | 1.00 Ref       | 1.00 Ref        | 1.00 Ref       |
| Female                    | 1.36 (1.10-1.68)| 0.004          | 1.51 (1.34-1.67)| 0.002          |
| Age (years)               |                |                |                |                |
| <30                       | 1.00 Ref.       | 1.00 Ref       | 1.00 Ref        | 1.00 Ref       |
| 30-39                     | 1.17 (0.85-1.63)| >0.05          | 1.02 (0.70-1.52)| >0.05          |
| 40-49                     | 1.34 (0.96-1.87)| >0.05          | 0.97 (0.64-1.48)| >0.05          |
| 50-59                     | 1.62 (1.07-2.43)| 0.02           | 1.11 (0.65-1.88)| >0.05          |
| Subjective health state   |                |                |                |                |
| Fair/rather fair          | 1.00 Ref.       | 1.00 Ref       | 1.00 Ref        | 1.00 Ref       |
| Neither fair nor poor     | 1.77 (1.38-2.28)| <0.001         | 1.54 (1.12-2.11)| 0.008          |
| Rather poor/poor          | 1.60 (1.13-2.26)| 0.008          | 1.21 (0.76-1.91)| >0.05          |
| Number of health problems |                |                |                |                |
| 0-3                       | 1.00 Ref.       | 1.00 Ref       | 1.00 Ref        | 1.00 Ref       |
| 1-3                       | 1.11 (0.82-1.49)| >0.05          | 1.01 (0.72-1.41)| >0.05          |
| 4-6                       | 1.71 (1.22-2.39)| 0.002          | 1.16 (0.77-1.75)| >0.05          |
| >7                        | 1.39 (0.84-2.30)| >0.05          | 0.86 (0.46-1.59)| >0.05          |
| Heart attack              |                |                |                |                |
| Yes                       | 2.41 (0.81-7.16)| >0.05          | 1.38 (0.37-5.09)| >0.05          |
| No                        | 1.00 Ref.       | 1.00 Ref       | 1.00 Ref        | 1.00 Ref       |
| High blood pressure       |                |                |                |                |
| Yes                       | 4.72 (2.99-7.46)| <0.001         | 3.92 (2.32-6.64)| <0.001         |
| No                        | 1.00 Ref.       | 1.00 Ref       | 1.00 Ref        | 1.00 Ref       |
| Diabetes                  |                |                |                |                |
| Yes                       | 2.63 (1.16-5.97)| 0.02           | 1.29 (0.46-3.59)| >0.05          |
| No                        | 1.00 Ref.       | 1.00 Ref       | 1.00 Ref        | 1.00 Ref       |
Table 2. Cont.

| Variable                                | Chance of Performing Blood Pressure Testing | Chance of Performing Cholesterol Level Testing |
|-----------------------------------------|--------------------------------------------|-----------------------------------------------|
|                                         | Unadjusted Model                          | Adjusted Model                                |
|                                         | OR (95% CI)                  | p-Value | OR (95% CI)                  | p-Value | OR (95% CI)                  | p-Value | OR (95% CI)                  | p-Value |
| Family history of chronic diseases      |                                            |         |                               |         |                               |         |                               |         |
| Yes                                     | 1.51 (1.17-1.95)               | 0.002   | 1.32 (0.99-1.75)               | 0.06    | 1.87 (1.37-2.56)               | <0.001  | 1.46 (1.03-2.07)               | 0.03    |
| No                                      | 1.00 Ref                       |         | 1.00 Ref                       |         | 1.00 Ref                       |         | 1.00 Ref                       |         |
| Total HLI                                |                                            |         |                               |         |                               |         |                               |         |
| 0-3                                     | 1.00 Ref                       |         | 1.00 Ref                       |         | 1.00 Ref                       |         | 1.00 Ref                       |         |
| 4-5                                     | 1.31 (0.94-1.84)               | >0.05   | 1.15 (0.79-1.68)               | >0.05   | 1.31 (1.31-2.48)               | <0.001  | 1.67 (1.16-2.41)               | 0.006   |

4. Discussion

This study provides an analysis of the correlates of BP and cholesterol level testing among a socially-disadvantaged population in Poland. Primary care physicians are often the only line of contact between a patient and healthcare system in the prevention of chronic diseases, including CVDs. They should play a key role in lifestyle examination and modification as well as the early identification and monitoring of health problems. In the current study the following correlates of a higher chance of BP and cholesterol level testing were identified: female gender, older age as well as health problems such as: heart attack, HBP and type 2 diabetes and a family history of chronic diseases. What is more, a higher healthy lifestyle index, indicating that the study participants have followed almost all of the studied recommendations related to the lifestyle, was a significant correlate of cholesterol level testing. This information is crucial for implementation of targeted preventive measures among this vulnerable population.

Epidemiological studies conducted in Poland in 1997–2017 have shown that hypertension occurs in 29% (NATPOL PLUS, 2002) to 45% (WOBASZ II, 2013–2014) of the adult population and even in 75% of people aged 65 years and over (PolSenior, 2007–2011) [9]. The NATPOL 2011 project has shown that prevalence of hypertension in Poland in adults below 80 years old was 32% [30].

In the WOBASZ II survey, hypercholesterolemia has been found in 70% of men and 64% of women. Isolated hypertriglyceridemia has been diagnosed in 6% of men and 2% of women. The prevalence of hypercholesterolemia has not changed significantly from 2003–2005. However, an increase in the incidence of hypertriglyceridemia has been found in men, and an increase in the incidence of low HDL-C levels has been observed in both sexes [31].

In the study of Kearney et al. performed by a representative method in 40 countries, it has been estimated that the incidence of hypertension in the world in 2000 was 26% (972 million people), and in 2025 it will increase to 29% (1560 million people) [15]. According to the WHO experts, increased BP is responsible for 13% of all deaths in the world [15,30]. Collins and MacMahon have shown that effective treatment of hypertension and a reduction in diastolic pressure of 5–6 mmHg reduces the risk of complications of coronary heart disease by 16%, and stroke by 38% [30]. A meta-analysis of 123 randomized control studies has shown that every 10 mmHg reduction in SBP resulted in a 20% reduction in the risk of serious cardiovascular incidents, reduction in the incidence of coronary heart disease, reduction in the frequency of strokes and heart failure, which ultimately led to up to 13% reduction in all-cause mortality [32].

In our study, 12% of the subjects declared HBP, which is lower than in other studies and can result from self-report. What is more, considering their financial situation, the study participants can pay more attention to their everyday needs than to their health state. Sixty-five percent of the beneficiaries of government welfare assistance declared having a BP test performed at least once within the year preceding the study. About 87% of the people who declared having AH indicated that they had previously had BP tests done. BP control up to \(<140/90\) mmHg is achieved in less than a quarter of the people diagnosed with hypertension and in a third of those treated for hypertension, even in countries...
with a well-structured healthcare system [33–35]. In Brazil, rates of effective BP control from 10% to 57% have been reported [36]. A study by Martínez-Valverde et al. reports effectiveness of a continuous intervention in medical education (CME) to improve adequate care for hypertension in controlling BP in hypertensive patients in primary care clinics in Mexico. Treatment by a family physician who participated in CME intervention reduced the likelihood of a lack of BP control by 53%. Adopting dietary recommendations reduced the likelihood of uncontrolled BP by 57% [37].

Ways to maintain the recommended cholesterol level and prevent or control HBP are simple and include: maintaining a regular physical activity, healthy weight, not drinking alcohol, and not smoking.

In our study, the healthy lifestyle index between 0 to 3 was noted for 84% of the respondents, and only 10% scored four out of five points. Only 0.6% of the people followed all 5 lifestyle recommendations. Those individuals who followed 4–5 recommendations performed BP testing and cholesterol level testing more often as compared to those who have not followed any of the recommendations (71.2% vs. 64.9%; \( p = 0.3 \) and 38.6% vs. 24.7%; \( p < 0.05 \)). This means that they generally represented positive attitudes towards health. On the other hand, people with an unhealthy lifestyle should constitute a target group for BP and cholesterol level checking as they have a higher risk of it and other related diseases. The testing can be also recognized as an element of healthy lifestyle counseling (as the elevated BP and/or cholesterol level can stimulate people to modify their lifestyles).

The recommended lifestyle changes that are effective in lowering BP include: reducing salt and alcohol intake, high fruit and vegetable intake, weight reduction and maintaining recommended body weight as well as a regular physical activity [38]. Also, smoking has a sharp, prolonged BP elevating effect, which may cause an increase in pressure during the 24-h monitoring period. Smoking cessation and other lifestyle changes have also other beneficial effects apart from lowering BP (e.g., reducing the risk of CVD or cancer) [5]. Lifestyle recommendations that effectively improve the plasma lipid profile include: reducing trans and saturated fat intake, increasing vegetable and fruit and fiber intake, reducing excess weight, and increasing physical activity. Smoking cessation has a positive effect on lipid parameters, including HDL-C concentration. [3].

Shah et al. have shown that a light exercise (such as aerobics) reduces BP and heart rate [39]. A regular low intensity and short duration physical activity reduces BP to a smaller extent than a moderate to intense physical activity but is associated with at least a 15% reduction in mortality in cohort studies [40,41]. Hurley et al. have proved that exercises act as prevention and treatment of metabolic syndrome, insulin resistance, abdominal obesity, hyperlipidemia, rheumatoid arthritis, and hypertension. Much smaller use of this method can be seen in the treatment of lipid disorders (however, it is a method that supports triglyceride control) [42]. Patients with hypertension should be advised to have at least 30 min of a moderate dynamic aerobic exercise (walking, cycling, running, or swimming) for 5–7 days a week.

In our analysis only 26% of the participants followed the recommendations for LTPA. An in-depth analysis focused on a LTPA and its correlates in our study population has been published previously [26]. This indicates that the men had a higher risk of inactivity during LTPA compared to the women. Higher odds of commuting physical inactivity (CPIA) were associated with unemployment, moderate and heavy drinking and having several health problems.

A diet, as a modifiable factor ensuring good health maintenance, reduces the risk of non-communicable chronic diseases and prevents a premature death [25]. Eating habits affect cardiovascular risk by affecting serum LDL and HDL cholesterol, BP, body weight, and glycemic control in diabetes. The Mediterranean diet has been shown to prevent development of CVD, breast cancer, colorectal cancer, depression, obesity, diabetes, asthma, erectile dysfunction and cognitive impairment [43,44]. The Mediterranean diet significantly reduces BP in 24-h measurements, glucose, and lipids [45]. Low consumption of potassium, magnesium, calcium, and at the same time, high consumption of sodium, saturated and trans-fatty acids, and cholesterol causes an increase in BP, while the DASH (dietary approaches to stop hypertension) diet lowers it [10].
A proper diet, rich in vegetables and fruit (especially containing potassium), with a reduced amount of saturated fat, helps to regulate BP. Studies show that men with low incomes and low levels of education eat vegetables and fruit less frequently [46,47], and less often follow fish guidelines [48]. A recent meta-analysis of the available studies has shown that a reduction in sodium intake of ~ 1.75 g per day (4.4 g salt per day) is associated with a reduction of SBP/DBP by an average of 4.2/2.1 mmHg and even greater hypotensive effect (~5.4/~2.8 mmHg) observed among people with hypertension [49]. An adequate diet should be accompanied by other changes, such as a physical activity and weight loss, drinking green or black tea may also have a small but significant BP-lowering effect [5,50,51]. In our study population only 9% of the participants met the criteria for a healthy diet. An in-depth analysis of the correlates of a diet in our study population has been already published [25]. Unhealthy eating habits dominated in all the groups regardless of the level of education of the subjects (p < 0.001). In the study by Michoty-Kotulska et al., irregularities have been also found in the nutritional behavior of physicians, such as: excessive consumption of sweets, wheat bread, sausages, and insufficient fruit, vegetables, fish, dairy, and wholemeal cereal products, which may lead to the development of diet-related diseases [52].

The most important clinical complications of obesity, in addition to hypertension, include: lipid disorders, insulin resistance, inflammation, and blood clotting, albuminuria, as well as development of diabetes and the occurrence of cardiovascular events [43]. In the meta-analyses, the average reduction of SBP and DBP with an average weight reduction of 5.1 kg was 4.4 and 3.6 mmHg, respectively [53]. The results of epidemiological studies indicate that obese people suffer from hypertension more often than people with normal body weight [54]. In our study, the recommended BMI range (18.5 and 24.9 (kg/m2)) was reported by 43% of the participants. According to WHO data, the percentage of overweight men in Poland is 43%, and women - 31%; percentage of obese people 25% and 26% respectively [55]. In Poland, in the NATPOL 2011 study, among people with BMI <25kg/m2, overweight, and obesity, the percentage of patients with hypertension (NT) was: 11%, 40%, and 60% in men and 18%, 38%, and 61% in women. In the adult population of Poles, significant relationships between SBP and DBP and BMI have been found at all ages, both in younger and older people [30]. Obesity increases the risk of developing type 2 diabetes 3–7 times, and a person with a BMI >35 has a 20-fold higher risk of developing diabetes than a person with a BMI within the normal range, while weight reduction is the main component of type 2 diabetes [54]. The survey of Abramczyk has shown that persons with normal body mass showed BP, triglyceride concentrations and total cholesterol concentrations close to normal more frequently. Obesity was most frequently recognized in patients who declared no physical activity [56]. Even a small reduction in body weight (by 5–10% of the initial value), reduces lipid disorders and has a positive effect on other cardiovascular risk factors common in people with lipid disorders [3]. Hypertension is also a big problem in diabetes, causing a significant threat to the cardiovascular system [57]. Hypertension increases the macro- and microvascular complications of diabetes, such as neuropathy, nephropathy, coronary artery disease, stroke and retinopathy [6]. The basis for CVD prevention in diabetic people, in addition to glycemic control, are the same general principles as for people without diabetes. Good control of BP and lipid levels is particularly important [43,58].

It is believed that reducing alcohol consumption and smoking cessation reduce BP by several mmHg [10]. The average prevalence of smoking in Europe is still high, at 20–35% [59]. Studies using ABPM have shown that smokers with normal BP as well as untreated hypertension have higher BP values during the day compared to non-smokers [60]. Smoking cessation has a positive effect on cardiovascular risk, and on HDL-C concentration, but special attention should be paid to preventing weight gain in those who quit smoking [61]. In our study, over 37% of the beneficiaries of government welfare assistance were smokers [24]. In the analysis by Milczarz et al. (on our study population), awareness of the health risk related to smoking was declared by 92% of the study participants, including 94% of women and 90% of men. More than a third of smokers have indicated that they wanted to quit. About a quarter of respondents did not make any decision to quit smoking. Our previous analyses
and the results from other studies stressed an urgent need to broaden knowledge about health risks of active and passive smoking, and that additional efforts should be made by healthcare professionals to disseminate that information together with effective help in quitting smoking (including counseling and treatment) [24,62,63].

Studies have shown that alcohol intake affects various biomarkers (lipids, BP, homocysteine, diabetes, haemostatic factors) associated with the risk of coronary heart disease. Reducing alcohol consumption, even in people who drink low to moderate amounts of alcohol, can have a positive effect on CVDs [64]. The WOBASZ (2003–2005) study found that moderate drinkers had a 37% higher risk of hypertension, a 25% higher risk of elevated triglyceride level, a 40% lower risk of low HDL-C levels, and a 35% lower risk of diabetes compared to light drinkers. Heavy alcohol consumption increased the likelihood of hypertension by 52%, hyperhomocysteinemia by 95%, elevated triglycerides by 46%, and decreased the likelihood of low HDL-C by 44% [65].

In our study, 56% of the participants followed the recommendations for alcohol consumption. Drinking men with hypertension should be advised to limit their alcohol consumption to 14 units per week, and women to 8 units per week (1 unit corresponds to 125 mL of wine or 250 mL of beer) [5]. Moderate alcohol consumption up to 20 g/d in men and 10 g/d in women is acceptable for people who consume alcoholic beverages, provided that the plasma TG concentration is not increased [3].

The education of patients suffering from hypertension and hypercholesterolemia should be multifaceted, including, in addition to raising awareness of the essence of the disease and the risk of its complications, also elements of a healthy lifestyle, including a physical activity, diet and smoking [16,66]. Aspects related to the preparation and proper techniques of measuring BP and factors affecting the value of the measurement are also important. The studies of Połetek et al. have shown that the largest percentage of patients derive knowledge about the correct measurement of BP from medical staff, mainly physicians, at 80% [67].

Several interventions at the population level have been effective in influencing individual lifestyles. Awareness and knowledge on how lifestyle risk factors lead to CVDs have increased in recent decades, and have contributed to reducing the prevalence of smoking and decreasing cholesterol levels. In addition, legal solutions favoring a healthy lifestyle, such as limiting salt intake and smoking bans, are cost-effective ways to prevent CVDs [68–71].

There are many perceived barriers to follow healthy lifestyle recommendations in vulnerable populations (such as beneficiaries of government welfare assistance), including individual and lifestyle issues, social and community barriers, living and working conditions, as well as cultural, socio-economic and environmental factors. What is more, they can believe that their health (and lifestyle-related behavior) is their personal responsibility. They can also experience lack of necessity to seek advice/counseling/treatment from professionals, lack of awareness of the available control measures/treatment, or misperceptions about the costs, safety, and side effects of the offered help/medications/procedures.

Patients should undergo regular follow-up visits (at least once a year) to measure BP in the office and outside it, as well as to check the CVDs risk profile [7]. The psychological aspect is also important. Measurements at a physician’s office give a patient the feeling that antihypertensive therapy is being properly controlled [72]. The latest recommendations also strengthen the role of measurements outside a physician’s office, i.e., measurements taken by a patient himself, as well as ABPM. These methods are very useful for verifying whether a patient has white coat hypertension or suspected masked hypertension. During a visit, a patient should receive recommendations for measuring BP and cholesterol level testing as basic method in the prevention of CVDs and atherosclerosis. Recommendations for lifestyle changes, which in the case of many patients will be a sufficient treatment, are also important [73].

The strengths and limitations of the study need to be pointed out. Firstly, this study has covered a disadvantaged population, which is usually less frequently covered by research and preventive measures. On the other hand, individuals belonging to such a population have a worse state of health
and a worse lifestyle than people from the general population and therefore, should be included in preventive measures and pro-health activities to an ever-larger extent. The response rate achieved in this study (50%) is comparable to the one observed in other epidemiological studies. The limitations of the study are mostly related to the cross-sectional study design, which limits the conclusions for causality; and self-reported data both for lifestyle related information and health status, which can be related to the response bias. Moreover, considering the extent of the study (that covered a number of actions, including epidemiological studies aimed at understanding the health status, health behaviors of the local community, as well as a broad number of activities in the field of health promotion) some data were not available for the current assessment. As an example, in addition to BMI, the waist/hip circumference measurement (which was not taken under the current study) would be more accurate to classify the people as overweight/obese.

5. Conclusions

Preventive measures seem to be the easiest way to reduce the risk of developing chronic diseases as well as to improve effectiveness of the treatment of the disease. Primary education and prevention focused on a lifestyle modification, as well as the improved detection of hypertension and hypercholesterolemia should be a priority in improving the population health.

In the current study, the following correlates of a higher chance of BP and cholesterol level testing were identified: female gender, older age, as well as health problems such as: heart attack, HBP, type 2 diabetes, and family history of chronic diseases. A higher healthy lifestyle index, indicating that the study participants have followed almost all of the studied recommendations related to the lifestyle, was a significant correlate of cholesterol level testing. Our study indicates the need to conduct campaigns to inform people about the effectiveness of lifestyle changes and about the necessity to control BP and cholesterol levels. Such actions should take into account the needs of the disadvantaged population and should especially target men, people with existing chronic diseases, and those with unfavorable lifestyle characteristics.

With respect to the socially-disadvantaged population, the social assistance institutions and outpatient clinics are the best places to conduct activities that promote healthy lifestyle. Studies suggest that the social community service organizations setting is a potentially effective way to reach disadvantaged people with an unfavorable lifestyle [74]. They have frequent and often continuous contact with their clients. Additionally, general practitioners should play the leading role in routine assessment of the patients’ risk (including lifestyle and health status assessment), recording it and referring to more specialized institutions if needed. Computerized systems, supported through government funding, should be considered in general practice and hospital settings. Health departments can also take a leading role in providing the social assistance staff with training in the delivery of a healthy lifestyle message at no cost to the service.

The most commonly used strategies to promote lifestyle changes can cover risk assessment, increasing awareness, emotional support and encouragement as well as referrals to specialists. Group counseling promoting a healthy lifestyle (focusing on a recreational physical activity, healthy/balanced diet, avoiding alcohol consumption, non-smoking, but also on promoting health examination/checkup, including weight control and BP and cholesterol testing) could be effective. Some general educational activities/campaigns dedicated to rural or disadvantaged populations are also crucial. There is evidence of an ‘inverse care law’ whereby health services are more accessible in the more affluent (and often less needy) areas and that patients from lower socioeconomic positions receive less preventive care from their doctors [74]. This underlined that such activities should be easily accessible, at low or no costs, especially in the case of people with a lower SES.

Author Contributions: D.K. and K.P. conceived the original idea for the analysis, participated in the statistical analyses and interpretation of the results; M.Z. wrote the draft of the manuscript. L.B.-R. contributed intellectually to the development of the final manuscript. All authors have read and agreed to the published version of the manuscript.
**Funding:** This research was funded by a grant from Norway through the Norway Grants and co-financed by the Polish state budget grant number: PL13-27/032/13/NMF/2015/00/2802/678 and by the Medical University of Łódź (503/6-024-01/503-66-001). A written permission has been provided for the data use. The funding body had no role in the design of the study and collection, analysis, and interpretation of the data and in writing the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. World Health Organization. World Health Statistics 2019: Monitoring health for the SDGs. 2019. Available online: https://www.who.int/gho/publications/world_health_statistics/2019/en/ (accessed on 20 January 2020).

2. World Health Organization. World Health Statistics 2018: Monitoring health for the SDGs. 2018. Available online: https://www.who.int/gho/publications/world_health_statistics/2018/en/ (accessed on 20 January 2020).

3. Catapano, A.L.; De Backer, G.; Wiklund, O.; Chapman, M.J.; Drexel, H.; Hoes, A.W.; Jennings, S.C.; Landmesser, U.; Pedersen, T.R.; Reiner, Ž.; et al. Wtymczne ESC/EAS dotyczące leczenia zaburzeń lipidowych w 2016 roku. *Kardiol. Pol.* 2016, 74, 1234–1318. [CrossRef] [PubMed]

4. Townsend, N.; Nichols, M.; Scarborough, P; Rayner, M. Cardiovascular disease in Europe—epidemiological update 2015. *Eur. Heart J.* 2015, 36, 2696–2705. [CrossRef] [PubMed]

5. Piepoli, M.F.; Hoes, A.W.; Agewall, S.; Albus, C.; Brotons, C.; Catapano, A.L.; Cooney, M.; Corrà, U.; Cosyns, B.; Deaton, C.; et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Eur. Heart J.* 2016, 37, 2315–2381. [CrossRef] [PubMed]

6. Kowalewski, W.; Hebel, K. Elevated blood pressure as cardiovascular risk factor. *Rocz. Pomor. Akad. Med. Szczec.* 2013, 59, 18–24.

7. Arnett, D.K.; Blumenthal, R.S.; Albert, M.A.; Buroker, A.B.; Goldberger, Z.D.; Hahn, E.J.; Himmlerfarb, C.D.; Khra, A.; Lloyd-Jones, D.; McEvoy, J.W.; et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J. Am. Coll. Cardiol.* 2019, 74, e177–e232. [CrossRef] [PubMed]

8. Williams, B.; Mancia, G.; Spiering, W.; Rosei, E.A.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; et al. Wtymczne ESC/ESH dotyczące postępowania w nadciśnieniu tętniczym (2018). *Kardiol. Pol.* 2019, 77, 71–159. [CrossRef] [PubMed]

9. Raport NFZ 2019. NFZ o Zdrowiu. Nadciśnienie Tętnicze. Warszawa, 2019. Available online: https://www.nfz.gov.pl\T1\guiisinglrightnfz\T1\guiisinglrightnadciisnienie-tetniczec-raport-nfz-2019-small (accessed on 20 January 2020).

10. Kniec, M.; Kujawska- Luczak, M. Impact of lifestyle risk factors on the occurrence for hypertension. *Forum Zaburzeń Metab.* 2012, 3, 14–23.

11. Peters, S.A.; Singhtateh, Y.; Mackay, D.; Huxley, R.R.; Woodward, M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: A systematic review and meta-analysis. *Atherosclerosis* 2016, 248, 123–131. [CrossRef]

12. Użarowska, M.; Surman, M.; Janik, M. Dwie twarze cholesterolu: Znaczenie fiziologiczne i udział w patogenezie wybranych chorób. *Kosm. Probl. Nauk Biol.* 2018, 67, 375–390. [CrossRef]

13. Łukaszewski, W.; Kregielska-Naroźna, M. Diagnostyka i leczenie zaburzeń lipidowych według wtymcznych Europejskiego Towarzystwa Kardiologicznego (ESC) i Europejskiego Towarzystwa Mijażdżowego (EAS) z 2016 roku. *Forum Zaburzeń Metab.* 2018, 9, 23–35.

14. Gumprecht, J. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2019. Stanowisko Polskiego Towarzystwa Diabetologicznego. *Diabetol. Prakt.* 2019, 5, 1–110.

15. Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension: Analysis of worldwide data. *Lancet* 2005, 365, 217–223. [CrossRef]

16. Tykarski, A.; Narkiewicz, K.; Gaciong, Z.; Januszewicz, A.; Litwin, M.; Kostka-Jeziorny, K. Zasady postępowania w nadciśnieniu tętniczym – 2015 roku. Wytymczne Polskiego Towarzystwa Naciśnienia Tętniczego. *Naciśnienie Tętnicze Prakt.* 2015, 1, 1–70.

17. Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Böhm, M.; Christiaens, T.; Cifkova, R.; de Backer, G.; Dominiczak, A.; et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. *Blood Press.* 2014, 23, 3–16. [CrossRef]
18. Tomasik, T. Prewencja chorób układu krążenia w podstawowej opiece zdrowotnej. Zdrowie Publiczne 2014, 12, 338–351.

19. Marcinowicz, L.; Pawlikowska, T.; Windak, A.; Chlabicz, S. Perceptions of an older patient on the role of the family doctor in health promotion: A qualitative case study. J. Med. Case Rep. 2013, 7, 57. [CrossRef]

20. Hicks, K.K.; Murano, P.S. Viewpoint Regarding the Limited Nutrition Education Opportunities for Physicians Worldwide. Educ. Prim. Care 2016, 27, 439–442.

21. Lazić, D.; Cikac, T.; Ozvacić, Z.; Cop, R. GPs’ intervention in changing lifestyle behavior of adipose patients. Acta Med. Croatica 2007, 61, 7–11.

22. Wałęska, E.; Sadowski, A.M.; Nowak, A.; Gądek, M.; Machnik, K. Tobacco smoking among patients with diseases of the cardiovascular system. Pielęgniarstwo Chir. Angiol. 2015, 3, 170–175.

23. Rozporządzenie Ministra Zdrowia z dnia 21 września 2016 r. w sprawie zakresu zadań lekarza podstawowej opieki zdrowotnej, pielęgniarki podstawowej opieki zdrowotnej i położnej podstawowej opieki zdrowotnej (Dz.U. z 2016, poz. 1567). Available online: https://www.sejm.gov.pl (accessed on 20 January 2020).

24. Milcarz, K.; Makowiec-Dąbrowska, T.; Bań-Romaniszyn, L.; Kaleta, D. Smoking Patterns and Smoking Cessation Willingness—a Study among Beneficiaries of Government Welfare Assistance in Poland. Int. J. Environ. Res. Public Health 2017, 14, 131. [CrossRef]

25. Kałucka, S.; Kaleta, D.; Makowiec-Dąbrowska, T. Prevalence and Correlates of Physical Inactivity during Leisure-Time and Commuting among Beneficiaries of Government Welfare Assistance in Poland. Int. J. Environ. Res. Public Health 2017, 14, 1126. [CrossRef] [PubMed]

26. Body Mass Index. Available online: http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi (accessed on 7 February 2020).

27. Lenz, T.L.; Gillespie, N.D.; Skradski, J.; Vierreck, L.K.; Packard, K.A.; Monaghan, M.S. Development of a composite lifestyle index and its relationship to quality of life improvement: The CLI pilot study. ISRN Prev. Med. 2013, 2013, 1–7. [CrossRef] [PubMed]

28. US Department of Health and Human Services; Office of Disease Prevention and Health Promotion. Physical Activity Guidelines for Americans. 2008. Available online: http://www.health.gov/paguidelines (accessed on 7 February 2020).

29. Zdrojewski, T.; Drygas, W.; Naruszewicz, M.; Kawecka-Jaszcz, K.; Jankowski, P. Nadciśnienie tętnicze w populacji ogólnej. Hipertensjologia 2015, 1–17. Available online: https://www.researchgate.net/publication/292986521_Nadciśnienie_świetnie_w_populacji_ogólnej (accessed on 20 January 2020).

30. Pajak, A.; Szafraniec, K.; Polak, M.; Polakowska, M.; Kozela, M.; Piotrowski, W.; Kwaśniewska, M.; Podolecka, E.; Kozakiewicz, K.; Tykarski, A.; et al. Changes in the Prevalence, Treatment, and Control of Hypercholesterolemia and Other Dyslipidemias Over 10 Years in Poland: The WOBASZ Study. Pol. Arch. Med. Wewn. 2016, 126, 642–652.

31. Ettehad, D.; Emdin, C.A.; Kiran, A.; Anderson, S.G.; Callender, T.; Emberson, J.; Chalmers, J.; Rodgers, A.; Rahimi, K. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet 2016, 387, 957–967. [CrossRef]

32. Wolf-Maier, K.; Cooper, R.S.; Kramer, H.; Banegas, J.R.; Giampaoli, S.; Pajak, A.; Szafraniec, K.; Polak, M.; Polakowska, M.; Kozela, M.; Piotrowski, W.; Kwansiewska, M.; Podolecka, E.; Kozakiewicz, K.; Tykarski, A.; et al. Changes in the Prevalence, Treatment, and Control of Hypercholesterolemia and Other Dyslipidemias Over 10 Years in Poland: The WOBASZ Study. Acta Med. Croatica 2007, 61, 7–11.

33. Pajak, A.; Szafraniec, K.; Polak, M.; Polakowska, M.; Kozela, M.; Piotrowski, W.; Kwaśniewska, M.; Podolecka, E.; Kozakiewicz, K.; Tykarski, A.; et al. Changes in the Prevalence, Treatment, and Control of Hypercholesterolemia and Other Dyslipidemias Over 10 Years in Poland: The WOBASZ Study. Pol. Arch. Med. Wewn. 2016, 126, 642–652.

34. Heneghan, C.; Perera, R.; Mant, D.; Glasziou, P. Hypertension guideline recommendations in general practice: Awareness, agreement, adoption, and adherence. Br. J. Gen. Pract. 2007, 57, 948–952. [CrossRef]

35. Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L., Jr.; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.T., Jr.; et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The JNC 7 Report. JAMA 2003, 289, 2560–2572.

36. Pinho Nde, A.; Pierin, A.M. Hypertension control in Brazilian publications. Arq. Bras. Cardiol. 2013, 101, e65–e73. [CrossRef]
37. Martínez-Valverde, S.; Castro-Ríos, A.; Pérez-Cuevas, R.; Klunder-Klunder, M.; Salinas-Escudero, G.; Reyes-Morales, H. Effectiveness of a medical education intervention to treat hypertension in primary care. *J. Eval. Clin. Pract.* 2012, 18, 420–425. [CrossRef] [PubMed]

38. Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Böhm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur. Heart J.* 2013, 34, 2159–2219.

39. Shah, S.; Hermanowski-Vosatka, A.; Gibson, K.; Ruck, R.A.; Jia, G.; Zhang, J.; Hwang, P.; Ryan, N.W.; Langdon, R.B.; Feig, P.J. Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. *J. Am. Soc. Hypertens.* 2011, 5, 166–176. [CrossRef] [PubMed]

40. Leitzmann, M.F.; Park, Y.; Blair, A.; Ballard-Barbash, R.; Mouw, T.; Hollenbeck, A.R.; Schatzkin, A. Physical activity recommendations and decreased risk of mortality. *Arch. Intern. Med.* 2007, 167, 2453–2460. [CrossRef]

41. Rossi, A.; Dikareva, A.; Bacon, S.L.; Daskalopoulou, S.S. The impact of physical activity on mortality in patients with high blood pressure: A systematic review. *J. Hypertens.* 2012, 30, 1277–1288. [CrossRef]

42. Hurley, B.F.; Hanson, E.D.; Sheaff, A.K. Strength training as a countermeasure to aging muscle and chronic disease. *Sports Med.* 2001, 41, 289–306. [CrossRef]

43. Piekut, M.F.; Hoes, A.W.; Geijer, S.; Brotons, C.; Catapano, A.L.; Cooney, M.T.; Corrá, U.; Cosyns, B.; Deaton, C.; et al. Wytyczne ESC dotyczące prewencji chorób układu sercowo-naczyniowego w praktyce klinicznej w 2016 roku. *Kardiol. Pol.* 2016, 74, 821–936. [CrossRef]

44. Widmer, R.J.; Flammer, A.J.; Lerman, L.O.; Lerman, A. The Mediterranean Diet, its Components, and Cardiovascular Disease. *Am. J. Med.* 2015, 128, 229–238. [CrossRef]

45. Doménech, M.; Roman, P.; Lapetra, J.; García de la Corte, F.J.; Sala-Vila, A.; de la Torre, R.; Corella, D.; Salas-Salvadó, J.; Ruiz-Gutiérrez, V.; Lamuela-Raventós, R.M.; et al. Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: One-year randomized, clinical trial. *Hypertension* 2014, 64, 69–76. [CrossRef]

46. Peche, R.; Monsivais, P.; Ng, Y.L.; Marteau, T.M. Why don’t poor men eat fruit? Socioeconomic differences in motivations for fruit consumption. *Appetite* 2015, 84, 271–279. [CrossRef]

47. Conklin, A.I.; Forouhi, N.G.; Suhrcke, M.; Surtees, P.; Wareham, N.J.; Monsivais, P. Variety more than quantity of fruit and vegetable intake varies by socioeconomic status and financial hardship. Findings from older adults in the EPIC cohort. *Appetite* 2014, 83, 248–255. [CrossRef] [PubMed]

48. Dijkstra, S.C.; Neter, J.E.; Brouwer, I.A.; Huisman, M.; Visser, M. Adherence to dietary guidelines for fruit, vegetables and fish among older Dutch adults; the role of education, income and job prestige. *J. Nutr. Health Aging* 2014, 18, 115–121. [CrossRef]

49. He, F.J.; Li, J.; MacGregor, G.A. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. *BMJ* 2013, 346, f1325. [CrossRef] [PubMed]

50. Li, G.; Zhang, Y.; Thabane, L.; Mbuagbaw, L.; Liu, A.; Levine, M.; Holbrook, A. Effect of green tea supplementation on blood pressure among overweight and obese adults: A systematic review and meta-analysis. *J. Hypertens.* 2015, 33, 243–254. [CrossRef]

51. Greiling, A.; Ras, R.T.; Zock, P.L.; Lorenz, M.; Hopman, M.T.; Thijsen, D.; Draijer, R. The effect of black tea on blood pressure: A systematic review with meta-analysis of randomized controlled trials. *PLoS ONE* 2014, 9, e103247. [CrossRef]

52. Michota-Katulska, E.; Zegan, M.; Leponika, M.; Kucharska, A.; Śirniska, B. Dietary habits in a selected group of medical doctors. *Zdrow. Człow.* 2016, 43, 239–249.

53. Neter, J.E.; Stam, B.E.; Kok, F.J.; Grobbee, D.E.; Geleijnse, J.M. Influence of weight reduction on blood pressure: A meta-analysis of randomized controlled trials. *Hypertension* 2003, 42, 878–884. [CrossRef]

54. Jarosz, M.; Rychlik, E. Obesity epidemic - what will our future look like? *Gastroenterol. Pol.* 2010, 17, 47–52.

55. Wojtyńiak, B.; Goryń, P. Raport. Sytuacja zdrowotna ludności Polski i jej uwarunkowania. NIZP-PZH. Warszawa 2018. Available online: https://www.pzh.gov.pl/najnowszy-raport-nizp-pzh-sytuacja-zdrowotna-ludnosci-polski-i-jej-uvwarkowania/ (accessed on 20 January 2020).

56. Abramczyk, A. Body mass, behaviours and social/health situation in diabetes patients at the level of primary medical healthcare: A Polish national study. *Kardiol. Pol.* 2013, 71, 493–501. [CrossRef]

57. Biswas, A.; Alvarez, A.; Mukherjee, D. Hypertension in diabetes: Optimal pharmacotherapy. *Cardiovasc. Hematol. Agents Med. Chem.* 2011, 9, 95–105. [CrossRef]
58. Inzucchi, S.E.; Bergenstal, R.M.; Buse, J.B.; Diamant, M.; Ferrannini, E.; Nauck, M.; Peters, A.L.; Tsapas, A.; Wender, R.; Matthews, D.R. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* **2015**, *38*, 140–149. [CrossRef]

59. Kotseva, K.; Wood, D.; de Bacquer, D.; de Backer, G.; Rydén, L.; Jennings, C.; Gyberg, V.; Amouyel, P.; Bruthans, J.; Conde, A.C.; et al. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. *Eur. J. Prev. Cardiol.* **2016**, *23*, 636–648. [CrossRef] [PubMed]

60. Groppelli, A.; Giorgi, D.M.; Omboni, S.; Parati, G.; Mancia, G. Persistent blood pressure increase induced by heavy smoking. *J. Hypertens.* **1992**, *10*, 495–499. [CrossRef] [PubMed]

61. Maeda, K.; Noguchi, Y.; Fukui, T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: A meta-analysis. *Prev. Med.* **2003**, *37*, 283–290. [CrossRef]

62. Milcarz, M.; Polańska, K.; Bąk-Romaniszyn, L.; Kaleta, D. How Social Care Beneficiaries in Poland Rate Relative Harmfulness of Various Tobacco and Nicotine-Containing Products. *Int. J. Environ. Res. Public Health* **2017**, *14*, 1029. [CrossRef] [PubMed]

63. Milcarz, M.; Polańska, K.; Bąk-Romaniszyn, L.; Kaleta, D. Tobacco Health Risk Awareness among Socially Disadvantaged People—a Crucial Tool for Smoking Cessation. *Int. J. Environ. Res. Public Health* **2018**, *15*, 2244. [CrossRef] [PubMed]

64. Holmes, M.V.; Dale, C.E.; Zuccolo, L.; Silverwood, R.J.; Guo, Y.; Ye, Z.; Prieto-Merino, D.; Dehghan, A.; Trompet, S.; Wong, A.; et al. InterAct Consortium. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. *BMJ* **2014**, *349*, g4164. [CrossRef]

65. Wasikiewicz, A.; Sygnowska, E. Alcohol intake and cardiovascular risk factor profile in men participating in the WOBASZ study. *Kardiol. Pol.* **2013**, *71*, 359–365. [CrossRef]

66. Wróblewska, J.; Klocok, M.; Czarnecka, D. Ocena spożycia wielonienasyconych kwasów tłuszczowych wśród młodych kobiet i mężczyzn chorujących na naczięcie tętnicze. *Przegl Lek* **2016**, *73*, 382–387.

67. Połtek, K.; Palasz, I.; Siwiec, A.; Olszanecka, A. Knowledge and practice towards home blood pressure measurements in patients with arterial hypertension. *Przegl Lek* **2018**, *75*, 442–447.

68. Collins, M.; Mason, H.; O’Flaherty, M.; Guzman-Castillo, M.; Critchley, J.; Capewell, S. An economic evaluation of salt reduction policies to reduce coronary heart disease in England: A policy modeling study. *Value Health* **2014**, *17*, 517–524. [CrossRef] [PubMed]

69. Mason, H.; Shoaibi, A.; Ghandour, R.; O’Flaherty, M.; Capewell, S.; Khatib, R.; Jabr, S.; Unal, B.; Sözmen, K.; Arfa, C.; et al. A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries. *PLoS ONE* **2014**, *9*, e84445. [CrossRef]

70. O’Keeffe, C.; Kabir, Z.; O’Flaherty, M.; Walton, J.; Capewell, S.; Perry, I.J. Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland. *BMJ Open* **2013**, *3*, e002837.

71. Moreira, P.V.; Baralid, I.G.; Moubarac, J.C.; Monteiro, C.A.; Newton, A.; Capewell, S.; O’Flaherty, M. Comparing different policy scenarios to reduce the consumption of ultra-processed foods in UK: Impact on cardiovascular disease mortality using a modelling approach. *PLoS ONE* **2015**, *10*, e0118353. [CrossRef] [PubMed]

72. Szymański, F.M. Standard and additional methods of blood pressure monitoring—what we should remember? *Chor. Serca Naczyn* **2013**, *10*, 243–249.

73. Stead, L.F.; Buitrago, D.; Preciado, N.; Sanchez, G.; Hartmann-Boyce, J.; Lancaster, T. Physician advice for smoking cessation. *Cochrane Database Syst. Rev.* **2013**, *5*, CD000165. [CrossRef] [PubMed]

74. Bonevski, B.; O’Brien, J.; Frost, S.; Yiow, L.; Oakes, W.; Barker, D. Novel setting for addressing tobacco-related disparities: A survey of community welfare organization smoking policies, practices and attitudes. *Health Educ. Res.* **2013**, *28*, 46–57. [CrossRef]